Abstract
Recent clinical observations have noted a high prevalence of hypertension and diabetes among patients hospitalized with COVID-19. However, whether these cardiovascular disease (CVD) risk factors independently drive mortality or merely reflect the advanced age of the most vulnerable patients has remained unclear. This study analyzed data from the prospective Dutch COVID-PREDICT cohort (n=1,604) to evaluate the relationship between hypertension, dyslipidemia, diabetes, and clinical outcomes. The findings demonstrate that the accumulation of these risk factors leads to a stepwise increase in 21-day mortality, independent of age and sex.
Introduction
Since the onset of the COVID-19 pandemic, age has been identified as the primary risk factor for severe disease and death. Concurrently, clinicians observed that many severely ill patients presented with comorbidities such as hypertension and diabetes. This raised a critical question for risk stratification: are these cardiovascular risk factors independent drivers of poor outcomes, or are they simply markers of the aging process?
To address this, researchers utilized the COVID-PREDICT initiative to investigate the time-to-event relationship between CVD risk factors and outcomes including mortality and ICU admission. By adjusting for age and sex, the study sought to isolate the specific impact of metabolic and cardiovascular health on the clinical course of COVID-19.
Methodology
The study analyzed a cohort of 1,604 adult patients admitted to eight Dutch hospitals (including two university centers) between February and July 2020. Inclusion required a positive PCR test or high suspicion based on CT imaging.
Surrogate Markers for Risk Factors
Given the challenges of obtaining comprehensive medical histories during a pandemic surge, the researchers used home medication lists as surrogate markers for CVD risk factors:
- Hypertension: Use of antihypertensive medication.
- Dyslipidemia: Use of lipid-lowering therapy.
- Diabetes: Use of antidiabetic medication.
The intensity of these conditions was further proxied by the number of medication classes prescribed (e.g., taking two or more types of glucose-lowering drugs indicated more advanced or difficult-to-manage diabetes).
Statistical Approach
The primary endpoint was mortality within 21 days of admission. Secondary endpoints included ICU admission and ICU-specific mortality. The team employed Kaplan-Meier survival curves and Cox-regression models, adjusting for age and sex, and in secondary analyses, for obesity, smoking, and history of ischemic heart disease.
Results
Of the 1,604 patients (mean age 66; 60.5% male), 19.2% reached the primary endpoint of mortality or discharge for palliative care within 21 days.
The Stepwise Increase in Risk
The presence of multiple risk factors was strongly associated with mortality. After adjusting for age and sex, patients with two or more risk factors faced a significantly higher risk compared to those with none:
- Cumulative Risk: The presence of ≥2 risk factors was associated with a 52% increase in mortality risk (HR 1.52, 95% CI 1.15–2.02).
- Medication Intensity: The severity of the underlying condition, as measured by medication burden, also predicted outcomes. Patients taking ≥2 classes of antidiabetics had an HR of 2.09, while those on ≥2 antihypertensives had an HR of 1.46.
The ICU Paradox
Interestingly, while CVD risk factors were potent predictors of mortality, they were not significantly associated with an increased rate of ICU admission. This suggests that the increased mortality observed in patients with multiple comorbidities may occur outside the ICU setting.
Discussion
The findings highlight a "stepwise" progression of risk: as metabolic and cardiovascular burdens accumulate, the body’s resilience against COVID-19 diminishes.
Diabetes as a Primary Driver
Among the factors studied, diabetes (proxied by antidiabetic use) showed the strongest independent association with mortality. This suggests that the specific pathophysiology of diabetes—potentially involving chronic inflammation, endothelial dysfunction, or impaired immune response—may uniquely exacerbate the viral impact of SARS-CoV-2.
Triage and Decision-Making
The lack of association between risk factors and ICU admission (the "ICU Paradox") warrants attention. The authors suggest this may reflect "triage bias" or shared decision-making. Patients with advanced age and multiple comorbidities might have been less likely to be admitted to the ICU in favor of palliative care, leading to higher mortality rates without a corresponding spike in ICU utilization.
Conclusion
This prospective study confirms that hypertension, dyslipidemia, and diabetes are independent predictors of short-term mortality in hospitalized COVID-19 patients. These factors provide prognostic value beyond age and sex alone. While the use of medication as a surrogate for diagnosis is a limitation, the clear stepwise increase in risk underscores the need for aggressive monitoring of patients with multiple metabolic comorbidities. Future research should focus on the biological mechanisms that make these patients particularly vulnerable to the systemic effects of COVID-19.
Summary updated